Global CAR T-Cell Therapy Market Size (2024 - 2029)

The CAR T-cell therapy market is projected to experience significant growth over the forecast period, driven by an increasing burden of cancer and enhanced research and development efforts in the field. The market's expansion is influenced by the rising demand for CAR T-cell therapies, as they offer innovative solutions for targeting cancer cells. Despite the challenges posed by the high costs associated with developing these therapies, the market is expected to grow due to the resumption of research activities and patient visits following the COVID-19 pandemic.

Market Size of Global CAR T-Cell Therapy Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
CAR T-Cell Therapy Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 4.88 Billion
Market Size (2029) USD 11.30 Billion
CAGR (2024 - 2029) 18.27 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

CAR T-Cell Therapy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

CAR T-Cell Therapy Market Analysis

The Global CAR T-Cell Therapy Market size is estimated at USD 4.88 billion in 2024, and is expected to reach USD 11.30 billion by 2029, growing at a CAGR of 18.27% during the forecast period (2024-2029).

The COVID-19 pandemic has significantly impacted the CAR T-cell therapy market. As per an article published in November 2021 in PubMed, CAR T-cell therapy recipients were believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state caused by prior lymphodepletion immunochemotherapy and CAR-T-cell therapy-related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. Such studies reflect that the onset of the COVID-19 pandemic reduced the number of patients undergoing CAR-T cell therapy, significantly impacting the demand for CAR-T-cell therapy. However, with the introduction of vaccines and uplifting lockdown restrictions, research and development activities have been resumed, and patient visits increased, reflecting that the market is expected to grow significantly in the coming period.

The market's growth can be attributed to the factors such as the increasing burden of cancer and the rise in research and development to develop CAR T-cell therapy. For instance, according to the Macmillan Cancer Support statistics updated in October 2022, the estimated number of people currently living with cancer in the UK are likely to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This estimation includes 1,010,310 number of males and 948,000 cases of females. Furthermore, as per a June 2021 update by the American Society of Clinical Oncology (ASCO), cancer cells are known to hide from the normal immune system, but through CAR T-cell therapy, scientists can make T cells better equipped to find and kill some cancer cells. Thus, the anticipated increase in cancer cases will drive the demand for CAR T-cell therapy in the coming period. Additionally, increasing research and development are contributing to market growth. For instance, in December 2021, Novartis reported the introduction of T-Charge, the company's next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. Furthermore, in January 2022, Bristol-Myers Squibb Company reported that Japan's Ministry of Health, Labour and Welfare approved Abecma (idecabtagene violence), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma. Such developments drive the demand for CAR T-cell therapies, thereby contributing to market growth.

Hence, due to the rise in cancer cases, and the increase in research and development in CAR T- cell therapy, the studied market is expected to witness growth over the forecast period. However, the high cost of developing CAR T-cell therapy is a major factor hindering market growth.

CAR T-Cell Therapy Industry Segmentation

As per the scope of the report, chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T cell receptor for use in immunotherapy. It modifies a person's immune system, making it more effective at fighting chronic disorders such as cancer and other disorders. The CAR T-Cell Therapy Market is Segmented by Types (Abecma, Breyanzi, Kymriah, Tecartus, Yescarta, and Others), Applications (Leukemia, Lymphoma, Multiple Myeloma, and Autoimmune Disorders, and Other Applications), End Users (Hospitals, Cancer Care Treatment Centers) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.

By Type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
Others
By Application
Leukemia
Lymphoma
Multiple Myeloma
Autoimmune Disorders
Other Application
By End User
Hospitals
Cancer Care Treatment Centers
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global CAR T-Cell Therapy Market Size Summary

The CAR T-cell therapy market is poised for substantial growth, driven by the increasing incidence of cancer and advancements in research and development. The market's expansion is supported by the rising demand for innovative cancer treatments, as traditional therapies often fall short in efficacy. The COVID-19 pandemic initially hindered market growth by reducing patient uptake due to the immunocompromised state of CAR T-cell therapy recipients. However, the resumption of research activities and increased patient visits post-vaccination have set the stage for a robust recovery and growth trajectory. The development of next-generation CAR T-cell platforms and regulatory approvals for new therapies further bolster market prospects, addressing the growing need for effective cancer treatments.

North America is expected to be a significant contributor to the market's growth, fueled by the high prevalence of cancer and autoimmune disorders, alongside a strong presence of established market players. The region's growth is further enhanced by strategic initiatives, such as the establishment of new manufacturing facilities and promising clinical trials. The competitive landscape is characterized by the presence of major players like Novartis AG, Bristol-Myers Squibb Company, and Gilead Sciences, Inc., who are actively engaging in partnerships, product launches, and geographical expansions to strengthen their market position. Despite the high cost of therapy development posing a challenge, the market is anticipated to witness continued growth, driven by increasing cancer cases and ongoing investments in CAR T-cell therapy innovations.

Explore More

Global CAR T-Cell Therapy Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Growing Burden of Cancer Worldwide

      2. 1.2.2 Increasing Invesment and Research and Development to Develop CAR T-Cell Therapy

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Developing CAR T-Cell Therapy

    4. 1.4 Porter Five Forces

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Type

      1. 2.1.1 Abecma

      2. 2.1.2 Breyanzi

      3. 2.1.3 Kymriah

      4. 2.1.4 Tecartus

      5. 2.1.5 Yescarta

      6. 2.1.6 Others

    2. 2.2 By Application

      1. 2.2.1 Leukemia

      2. 2.2.2 Lymphoma

      3. 2.2.3 Multiple Myeloma

      4. 2.2.4 Autoimmune Disorders

      5. 2.2.5 Other Application

    3. 2.3 By End User

      1. 2.3.1 Hospitals

      2. 2.3.2 Cancer Care Treatment Centers

      3. 2.3.3 Other End Users

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global CAR T-Cell Therapy Market Size FAQs

The Global CAR T-Cell Therapy Market size is expected to reach USD 4.88 billion in 2024 and grow at a CAGR of 18.27% to reach USD 11.30 billion by 2029.

In 2024, the Global CAR T-Cell Therapy Market size is expected to reach USD 4.88 billion.

CAR-T Cell Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)